Company intelligence
Resalis Therapeutics
Tackling metabolic disorders with non-coding RNAs
About Resalis Therapeutics
Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.
Verified activity
Signals from Resalis Therapeutics
4 published signals
Presence & Recognition
Resalis Therapeutics was featured in the Clarivate for Life Sciences & Healthcare Companies to Watch report highlighting its RNA-based approach targeting miR-22 and RES-010.
Reported by Resalis Therapeutics
Products & Services
Resalis Therapeutics announced that Diana Mathilde Røpcke will lead clinical strategy and drive the development of its lead candidate RES-010, an RNA-based therapeutic targeting the microRNA miR-22.
Reported by Resalis Therapeutics
People
Resalis Therapeutics welcomed Diana Mathilde Røpcke, MD, PhD, as Chief Medical Officer.
Reported by Resalis Therapeutics
People
Resalis Therapeutics welcomed Diana Ropcke as Chief Medical Officer.
Reported by Alessandro Toniolo